TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11710402

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) 20 g for 5 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study: 9020286

Group type: EXPERIMENTAL
Intervention: Goserelin acetate-flutamide combination
Number of subjects: 45000

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Strontium-89
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES)
Number of subjects: 45000

Group type: EXPERIMENTAL
Intervention: Total androgen blockade (TAB)
Number of subjects: 45000
Study: 7970852

Group type: EXPERIMENTAL
Intervention: LoFric catheter
Number of subjects: 31

Group type: COMPARATOR
Intervention: PVC catheter
Number of subjects: 31
Study: 3297732

Group type: EXPERIMENTAL
Intervention: Captopril therapy for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 10
Study: 30829206

Group type: EXPERIMENTAL
Intervention: Pyrus communis fruit extract loaded emulgel (5% w/w)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (without fruit extract)
Number of subjects: 13
Study: 29245259

Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (general anesthesia only)
Number of subjects: 175
Study: 26283229

Group type: EXPERIMENTAL
Intervention: SMS text reminders for adherence to artemether-lumefantrine and post-treatment review
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Automated SMS distribution system
Number of subjects: 20
Study: 23507773

Group type: EXPERIMENTAL
Intervention: 20 IU of intranasal insulin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 40 IU of intranasal insulin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (both doses)
Number of subjects: 104
Study: 21554245

Group type: EXPERIMENTAL
Intervention: Hypoxic absolute exercise (H-AE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypoxic relative exercise (H-RE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normoxic control (N-C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypoxic control (H-C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normoxic exercise (N-E)
Number of subjects: 60
Study: 19289933

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16899712

Group type: EXPERIMENTAL
Intervention: 240-kcal liquid meals
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 240-kcal solid meals
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water (240 ml)
Number of subjects: 9
Study: 15816266

Group type: EXPERIMENTAL
Intervention: ADA questionnaire for major diabetes risk factors
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) >25 kg/m2
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Waist/hip ratio
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Overall risk assessment
Number of subjects: 317
Study: 12575585

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine (Spleen‐Kidney tonifying)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 101
Study: 9040055

Group type: EXPERIMENTAL
Intervention: MCAF/MCP-1 in myocardial infarction at 3 hours (133 +/- 19 pg/ml)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: MCAF/MCP-1 in myocardial infarction at 9 hours (143 +/- 20 pg/ml)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: MCAF/MCP-1 in myocardial infarction at 24 hours (168 +/- 13 pg/ml)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation of MCAF/MCP-1 with IL-8 at 12 hours
Number of subjects: 41
Study: 7954745

Group type: EXPERIMENTAL
Intervention: Peppermint oil and ethanol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Peppermint oil, eucalyptus oil, and ethanol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3309198

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX) as prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiation therapy as prophylaxis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isolated CNS relapse
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiple CNS relapses
Number of subjects: 100
Study: 27853872

Group type: EXPERIMENTAL
Intervention: Psychosomatic treatment for the elderly (5-week therapy)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Waiting time (5-week control condition)
Number of subjects: 116
Study: 27632917

Group type: EXPERIMENTAL
Intervention: High MUFA:SFA ratio ground beef (HR = 1.1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low MUFA:SFA ratio ground beef (LR = 0.71)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Self-selected washout diet (SS)
Number of subjects: 13
Study: 24477298

Group type: EXPERIMENTAL
Intervention: EVEN protein distribution (31.5 ± 1.3 g at breakfast, 29.9 ± 1.6 g at lunch, 32.7 ± 1.6 g at dinner)
Number of subjects: 8

Group type: COMPARATOR
Intervention: SKEW protein distribution (10.7 ± 0.8 g at breakfast, 16.0 ± 0.5 g at lunch, 63.4 ± 3.7 g at dinner)
Number of subjects: 8
Study: 22704410

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba leaf tablets, 19.2 mg each dose, taken 3 times a day for 6 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study: 20728068

Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (standard analgesic administration)
Number of subjects: 90
Study: 18462573

Group type: EXPERIMENTAL
Intervention: SSRIs + Cognitive Behaviour Therapy (CBT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: SSRIs only
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: SSRIs + CBT
Number of subjects: 208
Study: 16188920

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14733799

Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 125
Study: 10921167

Group type: EXPERIMENTAL
Intervention: Combined method of acupuncture with pressure on otopoints
Number of subjects: 86

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 86

Group type: COMPARATOR
Intervention: Simple pressure on otopoints
Number of subjects: 86
Study: 8832448

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg/kg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg, Atracurium 0.5 mg/kg, Succinylcholine 1 mg/kg
Number of subjects: 144
Study: 1417430

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride plus clinical management (CM)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Placebo plus clinical management (CM)
Number of subjects: 198
Study: 6701786

Group type: EXPERIMENTAL
Intervention: Hickman catheter (HC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyvinylchloride central venous catheters (CVC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hickman catheter (HC) (non-randomized group)
Number of subjects: 0
Study: 30611960

Group type: EXPERIMENTAL
Intervention: High-dose baclofen (30–270 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30424822

Group type: EXPERIMENTAL
Intervention: Physical activity intervention program (PA), including energy-restricted Mediterranean diet and behavioral support.
Number of subjects: 6059

Group type: COMPARATOR
Intervention: Control group with Mediterranean diet recommendations without calorie restriction or PA advice.
Number of subjects: 6059
Study: 26440134

Group type: EXPERIMENTAL
Intervention: 4 × 4‐min high‐intensity interval training (4HIIT) at 85%‐95% of HRmax
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 × 1‐min HIIT (1HIIT) at V˙O2max load
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 45‐min moderate‐intensity continuous training (MICT) at 70% of HRmax
Number of subjects: 30
Study: 24140664

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: COMPARATOR
Intervention: UFH+GPI
Number of subjects: 3602
Study: 22524767

Group type: EXPERIMENTAL
Intervention: Extrahepatic ipsilateral portal vein branch ligation (Group A)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Suture ligation of the cut surface vessels only (Group B)
Number of subjects: 26
Study: 20172688

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids levels
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: PUFA levels
Number of subjects: 411
Study: 17926440

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419
Study: 16291099

Group type: EXPERIMENTAL
Intervention: Surgical group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Surgical group at L4-5
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative group at L4-5
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Surgical group at L5-S1
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative group at L5-S1
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Surgical group central herniations at L4-5
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative group central herniations at L4-5
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Surgical group central herniations at L5-S1
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative group central herniations at L5-S1
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Surgical group paracentral herniations at L4-5
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative group paracentral herniations at L4-5
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Surgical group paracentral herniations at L5-S1
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonoperative group paracentral herniations at L5-S1
Number of subjects: 88
Study: 12671572

Group type: EXPERIMENTAL
Intervention: RIK mattress (KCI)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Nimbus 3 mattress (Huntleigh Healthcare)
Number of subjects: 158
Study: 10588806

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials identified in prosthodontic journals
Number of subjects: 62

Group type: COMPARATOR
Intervention: Screening of articles
Number of subjects: 62
Study: 8786520

Group type: EXPERIMENTAL
Intervention: Acamprosate (n = 63)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 127
Study: 1994935

Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6381019

Group type: EXPERIMENTAL
Intervention: Combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mean dosage of 444 mg levodopa and benserazide
Number of subjects: 125
Study: 29941233

Group type: EXPERIMENTAL
Intervention: Fish oil containing lipid emulsion (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Soybean oil containing lipid emulsion (n = 30)
Number of subjects: 60
Study: 28498507

Group type: EXPERIMENTAL
Intervention: aPDT + ST
Number of subjects: 20

Group type: COMPARATOR
Intervention: ST only
Number of subjects: 20
Study: 27111335

Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Number of subjects: 220
Study: 24335227

Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (tPA) plus endovascular therapy
Number of subjects: 656

Group type: COMPARATOR
Intervention: Intravenous tPA therapy alone
Number of subjects: 656
Study: 22494956

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg once daily
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study: 20646010

Group type: EXPERIMENTAL
Intervention: Frequent, low-intensity exercise (walking and cycling) for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 50
Study: 17951501

Group type: EXPERIMENTAL
Intervention: Dietary inulin-type fructans
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study: 15864937

Group type: EXPERIMENTAL
Intervention: Tramadol infusion (1 mg/kg loading dose at skin closure and 0.2 mg/kg/h postoperative infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine PCA alone (control group received saline infusion)
Number of subjects: 60
Study: 11302351

Group type: EXPERIMENTAL
Intervention: Physician-based exercise counseling
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 355
Study: 9088586

Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg daily for 4 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8154887

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 5'-DFUR at a daily oral dose of 600 mg/patient
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 5'-DFUR for 2 weeks at a daily oral dose of 1,200 mg/patient followed by 2 weeks of no treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 5'-DFUR
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 5'-DFUR
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both treatment regimens (continuous and intermittent)
Number of subjects: 55
Study: 3525336

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 149

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 149
Study: 29806569

Group type: EXPERIMENTAL
Intervention: Hand‐wrist resting orthosis
Number of subjects: 82

Group type: COMPARATOR
Intervention: Epicondylitis bandage
Number of subjects: 82
Study: 26928148

Group type: EXPERIMENTAL
Intervention: Extended labor for at least 1 additional hour
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual labor (expedited delivery via cesarean or operative vaginal delivery)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Extended labor
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual labor
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Extended labor and Usual labor
Number of subjects: 78
Study: 24885545

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lumbar epidural analgesia (LEA)
Number of subjects: 120
Study: 22910528

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1g/d
Number of subjects: 81

Group type: COMPARATOR
Intervention: Docosahexaenoic acid (DHA) 1g/d
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (coconut oil)
Number of subjects: 81
Study: 20923370

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 2316

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 2316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2316
Study: 18292675

Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nitrous oxide-free gas mixtures
Number of subjects: 14
Study: 16936431

Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day po) for 2 weeks before CABG
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 24
Study: 14499204

Group type: EXPERIMENTAL
Intervention: Primidone 250 mg/day (G 250)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Primidone 750 mg/day (G 750)
Number of subjects: 113
Study: 10923755

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg doses, three times)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9490141

Group type: EXPERIMENTAL
Intervention: Antireflux mechanism
Number of subjects: 70

Group type: COMPARATOR
Intervention: Afferent tubular segment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 1350264

Group type: EXPERIMENTAL
Intervention: M27 beta marker for detecting hyperpolymorphic locus DXS255
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M27 beta and other related markers
Number of subjects: 0
Study: 6756932

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d. (twice daily)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg added after 2 weeks of Metoprolol 100 mg b.i.d.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Metoprolol 200 mg b.i.d. (twice daily)
Number of subjects: 103
Study: 30817733

Group type: EXPERIMENTAL
Intervention: MNM group
Number of subjects: 187
Study: 29913292

Group type: EXPERIMENTAL
Intervention: Single-level transforaminal lumbar interbody fusion (TLIF) for Group K (kyphotic alignment)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Single-level transforaminal lumbar interbody fusion (TLIF) for Group L (non-kyphotic alignment)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Preoperative condition for Group K
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Postoperative condition for Group K
Number of subjects: 134
Study: 27828712

Group type: EXPERIMENTAL
Intervention: T'ai chi (24-posture yang style) for 50 min, three times per week for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Routine hospital rehabilitation program
Number of subjects: 38
Study: 24672936

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment, needling at relative points, once daily for 5 consecutive days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received inotropic agents, preload and afterload reducing therapy, anti-infection, etc.
Number of subjects: 60
Study: 22051941

Group type: EXPERIMENTAL
Intervention: PHEN/TPM CR 3.75/23 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHEN/TPM CR 15/92 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19652065

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m² 24-hour intravenous infusion once every 3 weeks (q3 weeks 24-hour)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Trabectedin 0.58 mg/m² 3-hour IV infusion every week for 3 weeks of a 4-week cycle (qwk 3-hour)
Number of subjects: 270
Study: 17473123

Group type: EXPERIMENTAL
Intervention: Active immunization for rotavirus diarrhea as part of well child preventive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptomatic relief as indicated case by case
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydration therapy
Number of subjects: 0
Study: 16803736

Group type: EXPERIMENTAL
Intervention: Four levels of geriatric care management
Number of subjects: 0
Study: 12719050

Group type: COMPARATOR
Intervention: Intravenous (i.v.) fentanyl 0.5 microg/kg before skin incision and no wound infiltration
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Wound infiltration with ropivacaine 0.375%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Wound infiltration with ropivacaine 0.375% combined with fentanyl 0.5 microg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (including both infiltration groups and i.v. fentanyl)
Number of subjects: 45
Study: 10389006

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 53

Group type: COMPARATOR
Intervention: Arthrography
Number of subjects: 53
Study: 8659967

Group type: EXPERIMENTAL
Intervention: Double gloves (method B: normal gloves inside, larger gloves outside)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Double gloves (method C: larger gloves inside, normal gloves outside)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Double gloves (method D: two pairs of normal size gloves)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single gloves (control)
Number of subjects: 32
Study: 1862204

Group type: EXPERIMENTAL
Intervention: Phenelzine 60 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenelzine 45 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6352278

Group type: EXPERIMENTAL
Intervention: Levonantradol (0.5 mg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Chlorpromazine (25 mg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Levonantradol (higher doses)
Number of subjects: 108
Study: 31918720

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, n=8; 65.25g fructose + 79.75g glucose, 1.8g carbohydrate/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Flavor-matched placebo (PLA, n=6)
Number of subjects: 14
Study: 29888454

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 241
Study: 28673877

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.03μg·Kg‐1·min‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05μg·Kg‐1·min‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.08μg·Kg‐1·min‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1μg·Kg‐1·min‐1
Number of subjects: 13

Group type: COMPARATOR
Intervention: NAVA
Number of subjects: 13

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 13
Study: 26141671

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 42
Study: 23171069

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21198803

Group type: EXPERIMENTAL
Intervention: Dementia family care programme
Number of subjects: 92

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 92